Unknown

Dataset Information

0

Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases.

ABSTRACT: Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression of the disease, probably also decreasing morbidity and hospitalization rates, and improving patients' comfort. When the patent on infliximab started to expire, the first biosimilar of a monoclonal antibody was introduced onto the pharmacological market. Biosimilar infliximab was studied in rheumatology and proved a high similarity to the reference drug. Based on extrapolation, biosimilars were approved to treat adult and paediatric IBD patients. Biosimilar infliximab, mainly because of its lower cost, has started to be in common use in Europe. The first studies have shown a similar efficacy and safety profile in comparison with reference drug. Biosimilar infliximab is raising hopes for improving the availability of this effective treatment.

SUBMITTER: Sieczkowska J 

PROVIDER: S-EPMC4984328 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases.

Sieczkowska Joanna J   Jarzębicka Dorota D   Meglicka Monika M   Oracz Grzegorz G   Kierkus Jaroslaw J  

Therapeutic advances in gastroenterology 20160522 5

Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression of the disease, probably also decreasing morbidity and hospitalization rates, and improving patients' comfort. When the patent on infliximab started to expire, the first biosimilar of a monoclonal anti  ...[more]

Similar Datasets

Unknown Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.
| S-EPMC4830106 | biostudies-literature
Unknown Switching from originator infliximab to the biosimilar CT-P13 in 313 patients with inflammatory bowel disease.
| S-EPMC6187418 | biostudies-literature
Unknown Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.
| S-EPMC5487700 | biostudies-other
Unknown Post-marketing analysis for biosimilar CT-P13 in inflammatory bowel disease compared with external data of originator infliximab in Japan.
| S-EPMC8451807 | biostudies-literature
Unknown Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
| S-EPMC5284338 | biostudies-literature
Unknown Systematic Review: Non-medical Switching of Infliximab to CT-P13 in Inflammatory Bowel Disease.
| S-EPMC7369127 | biostudies-literature
Unknown Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results.
| S-EPMC5640013 | biostudies-other
Unknown Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn's disease and ulcerative colitis.
| S-EPMC4926778 | biostudies-literature
Unknown The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis.
| S-EPMC6767082 | biostudies-other
Unknown Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study.
| S-EPMC8742653 | biostudies-literature